Sinovac Biotech Ltd., a leading provider of biopharmaceutical products in China, announced that it has received a positive decision from the World Health Organization on the acceptability, in principle, of its Healive, a hepatitis A vaccine product, for purchase by United Nations agencies.
The Company’s Healive product was assessed according to the WHO Prequalification Procedure.
Mr. Weidong Yin, Chairman, President and CEO of the Company, commented that “I am very pleased that Healive has passed the assessment under WHO Prequalification procedures. This is an important milestone for Sinovac which we expect will provide opportunities to supply this vaccine to respective UN agencies as well as accelerate the regulatory approval process for this vaccine in international countries outside China.”
Sinovac Biotech Ltd. is a China-based biopharmaceutical company that focuses on the research, development, manufacturing and commercialization of vaccines that protect against human infectious diseases. Sinovac’s product portfolio includes vaccines against enterovirus71, or EV71, hepatitis A and B, seasonal influenza, H5N1 pandemic influenza (avian flu), H1N1 influenza (swine flu), and mumps.